News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/mehta-parinda-230.jpg)
HSCT approach provides ‘excellent’ survival in FA
- Author:
- Jen Smith
SALT LAKE CITY—A “risk-adjusted” approach leads to “excellent” survival in patients with Fanconi anemia (FA) undergoing alternative donor...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/godara-amandeep-240.jpg)
Study confirms higher risk of infection with CB transplant
- Author:
- Jen Smith
SALT LAKE CITY—Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/bmt-tandem-crowd-240.jpg)
Team identifies biomarkers for cGVHD in kids
- Author:
- Jen Smith
SALT LAKE CITY—Researchers say they have identified prognostic biomarkers for chronic graft-vs-host disease (cGVHD) in children. The group found...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/horwitz-mitchell-230.jpg)
Expanded UCB product can stand alone
- Author:
- Jen Smith
SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Bolanos-Meade-230-1.jpg)
Minihaplo-BMT can cure severe hemoglobinopathies
- Author:
- Jen Smith
SALT LAKE CITY—Cure of severe hemoglobinopathies is now possible for most patients, according to a speaker at the 2018 BMT Tandem Meetings....
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/osman-keren-md-JS-235.jpg)
Regimen deemed ‘safe and feasible’ in MM
- Author:
- Jen Smith
SALT LAKE CITY—A novel transplant regimen is “safe and feasible” for patients with multiple myeloma (MM), according to a presentation at the 2018...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/kim_youn_credit_larryyoung-220.jpg)
Antibody has ‘very promising activity’ in rel/ref CTCL
- Author:
- Jen Smith
LA JOLLA, CA—An antibody targeting KIR3DL2 has “very promising activity” in relapsed/refractory cutaneous T-cell lymphoma (CTCL), according to a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/bradley_haverkos_credit_larry_young_230.jpg)
Drug appears safe and active in PTCL, CTCL
- Author:
- Jen Smith
LA JOLLA, CA—The dual PI3K δ/γ inhibitor tenalisib has demonstrated activity in a phase 1 trial of patients with relapsed/refractory T-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/youngil_koh_credit_larry_young_230.jpg)
FDG PET can’t replace BM biopsy, study suggests
- Author:
- Jen Smith
LA JOLLA, CA—Fluorodeoxyglucose positron emission tomography (FDG PET) cannot replace bone marrow (BM) biopsy in T-cell lymphomas, according to a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/querfeld-christiane-credit-larryyoung-230.jpg)
Inhibitor provides clinical improvement in MF
- Author:
- Jen Smith
LA JOLLA, CA—Results of a phase 1 trial suggest MRG-106 can provide clinical improvement in patients with mycosis fungoides (MF), whether the drug...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/TCLF2018-session-larryyoung-230.jpg)
Drug may be option for B- and T-cell lymphomas
- Author:
- Jen Smith
LA JOLLA, CA—The EZH1/2 inhibitor DS-3201b could be a novel therapeutic option for non-Hodgkin lymphoma (NHL), according to a speaker at the 10th...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/huang-huiqiang-larryyoung-230.jpg)
Favorable results with chidamide in rel/ref NKTCL
- Author:
- Jen Smith
LA JOLLA, CA—Results of a phase 2 study suggest chidamide can produce durable responses in patients with relapsed/refractory natural killer/T-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/lorenzo_falchi_larryyoung_230.jpg)
Combo is preferentially active in T-cell lymphomas
- Author:
- Jen Smith
LA JOLLA, CA—A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/tclf2018-posters-larryyoung-190.jpg)
Duvelisib combos show promise for PTCL, CTCL
- Author:
- Jen Smith
LA JOLLA, CA—Phase 1 results suggest duvelisib combination therapies can be active and well-tolerated in patients with relapsed/refractory T-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/kim_youn_credit_larryyoung-220.jpg)
Mogamulizumab is ‘valuable’ option for CTCL
- Author:
- Jen Smith
LA JOLLA, CA—Mogamulizumab is a valuable new therapeutic option for patients with cutaneous T-cell lymphoma (CTCL), according to researchers....